Clinical Focus

  • Neurology

Academic Appointments

Administrative Appointments

  • Physician Director, RITE program, Stanford Healthcare (2019 - 2019)
  • Associate Medical Director, Stanford Neuroscience Healthcare Center (2019 - Present)
  • Associate Physician Improvement Leader for Department of Neurology, Stanford University (2017 - Present)
  • Co-Director, Advanced Clinical Skills, Stanford School of Medicine (2018 - Present)
  • Director, Movement Disorder Fellowship, Stanford University (2018 - Present)

Professional Education

  • Residency:University of Southern California Keck School of Medicine Registrar (2013) CA
  • Board Certification: Neurology, American Board of Psychiatry and Neurology (2013)
  • Medical Education:University of Vermont College of Medicine (2009) VT
  • Fellowship:University of California Los Angeles School of MedicineCA
  • Internship:Loma Linda University - School of MedicineCA


2019-20 Courses


All Publications

  • A Medical Legal Curriculum for Residents to Increase Physician Comfort in Patient Interactions Therkelsen, K., Yang, L. LIPPINCOTT WILLIAMS & WILKINS. 2019
  • Quantifying the burden of unfilled clinic appointment slots created by late-notice cancellations Wang, H. H., Batino, N., Yang, L. T. LIPPINCOTT WILLIAMS & WILKINS. 2019
  • Expert Patient Tutors: The Eradication of Neurophobia Hadley, G., Evans, R., Yang, L., Santini, V., De Luca, G. LIPPINCOTT WILLIAMS & WILKINS. 2018
  • Feature visualization and classification for the discrimination between individuals with Parkinson's disease under levodopa and DBS treatments BIOMEDICAL ENGINEERING ONLINE Machado, A. R., Zaidan, H. C., Souza Paixao, A. P., Cavalheiro, G. L., Monteiro Oliveira, F. H., Ferreira Barbosa Junior, J. A., Naves, K., Pereira, A. A., Pereira, J. M., Pouratian, N., Zhuo, X., O'Keeffe, A., Sharim, J., Bordelon, Y., Yang, L., Vieira, M. F., Andrade, A. O. 2016; 15


    Over the years, a number of distinct treatments have been adopted for the management of the motor symptoms of Parkinson's disease (PD), including pharmacologic therapies and deep brain stimulation (DBS). Efficacy is most often evaluated by subjective assessments, which are prone to error and dependent on the experience of the examiner. Our goal was to identify an objective means of assessing response to therapy.In this study, we employed objective analyses in order to visualize and identify differences between three groups: healthy control (N = 10), subjects with PD treated with DBS (N = 12), and subjects with PD treated with levodopa (N = 16). Subjects were assessed during execution of three dynamic tasks (finger taps, finger to nose, supination and pronation) and a static task (extended arm with no active movement). Measurements were acquired with two pairs of inertial and electromyographic sensors. Feature extraction was applied to estimate the relevant information from the data after which the high-dimensional feature space was reduced to a two-dimensional space using the nonlinear Sammon's map. Non-parametric analysis of variance was employed for the verification of relevant statistical differences among the groups (p < 0.05). In addition, K-fold cross-validation for discriminant analysis based on Gaussian Finite Mixture Modeling was employed for data classification.The results showed visual and statistical differences for all groups and conditions (i.e., static and dynamic tasks). The employed methods were successful for the discrimination of the groups. Classification accuracy was 81 ± 6% (mean ± standard deviation) and 71 ± 8%, for training and test groups respectively.This research showed the discrimination between healthy and diseased groups conditions. The methods were also able to discriminate individuals with PD treated with DBS and levodopa. These methods enable objective characterization and visualization of features extracted from inertial and electromyographic sensors for different groups.

    View details for DOI 10.1186/s12938-016-0290-y

    View details for Web of Science ID 000391062100001

    View details for PubMedID 28038673

    View details for PubMedCentralID PMC5203727

  • Platelet mitochondrial activity and pesticide exposure in early Parkinson's disease MOVEMENT DISORDERS Bronstein, J. M., Paul, K., Yang, L., Haas, R. H., Shults, C. W., Le, T., Ritz, B. 2015; 30 (6): 862-866


    Mitochondrial dysfunction has been implicated in the pathogenesis of Parkinson's disease (PD), but the cause of this dysfunction is unclear.Platelet mitochondrial complex I and I/III (nicotinamide adenine dinucleotide cytochrome c reductase, NCCR) activities were measured in early PD patients and matched controls enrolled in a population-based case-control study. Ambient agricultural pesticide exposures were assessed with a geographic information system and California Pesticide Use Registry.In contrast to some previous reports, we found no differences in complex I and I/III activities in subjects with PD and controls. We did find that NCCR activity correlated with subjects' exposure to pesticides known to inhibit mitochondrial activity regardless of their diagnosis.Electron transport chain (ETC) activity is not altered in PD in this well-characterized cohort when compared with community-matched controls but appears to be affected by environmental toxins, such as mitochondria-inhibiting pesticides.

    View details for DOI 10.1002/mds.26164

    View details for Web of Science ID 000354731500021

    View details for PubMedID 25757798

Footer Links:

Stanford Medicine Resources: